Here are 1-3 brief analogies to describe Cabaletta Bio:

• It's like Kite Pharma (known for CAR-T cancer therapies), but Cabaletta Bio uses similar advanced T-cell engineering to fight *autoimmune diseases* by targeting specific disease-causing B cells.
• Think of it as a specialized Novartis or Bristol Myers Squibb, developing cutting-edge cell therapies (akin to CAR-T) to selectively destroy problematic B cells that cause autoimmune conditions, rather than cancerous cells.

Cabaletta Bio's major product candidates include:

• DSG3-CAART: A CAAR T cell therapy in Phase I clinical trials for mucosal pemphigus vulgaris and Hemophilia A with Factor VIII alloantibodies.
• MuSK-CAART: A preclinical stage CAAR T cell product targeting a subset of patients with myasthenia gravis.
• FVIII-CAART: A discovery stage CAAR T cell product developed to treat a subset of patients with Hemophilia A.
• DSG3/1-CAART: A discovery stage CAAR T cell product for the treatment of mucocutaneous pemphigus vulgaris.

Cabaletta Bio (CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its product candidates are in various stages of clinical development, including Phase I, preclinical, and discovery stages.

As a clinical-stage company, Cabaletta Bio is primarily engaged in research and development activities and has not yet commercialized any products. Therefore, the company does not currently have major commercial customers in the traditional sense of selling products or services to other companies or individuals.

Steven Nichtberger, M.D. President, Chief Executive Officer, and Co-Founder

Steven Nichtberger has served as Chief Executive Officer, President, and Chairman of Cabaletta Bio since its founding in 2017. He is also a senior fellow and professor of practice at the Wharton School of the University of Pennsylvania. Dr. Nichtberger was the founding CEO of Tengion from 2004 to 2011, where he advanced regenerative medicine products and raised $230 million, including an IPO. His leadership at Tengion was recognized with the Ernst & Young Entrepreneur of the Year award for emerging companies in 2008. Earlier in his career, he was the head of global marketing for Merck and held various commercial operating roles at the company from 1995 to 2003. He is also a managing partner of GBF, LLC, which invests in and advises healthcare companies.

Anup Marda, MBA Chief Financial Officer

Anup Marda was appointed Chief Financial Officer of Cabaletta Bio in January 2019. Prior to joining Cabaletta, Mr. Marda served as Vice President and Head of Global Corporate Financial Planning & Analysis at Bristol-Myers Squibb (BMS). At BMS, he spent four years in leadership roles supporting R&D, where he led a team providing financial and business support for various groups including Discovery, Translational Medicine, Pharmaceutical Development, Global Clinical Operations, Global Regulatory, Operations, and Global Medical. He also served as head of Finance, R&D Portfolio Management, World-wide Commercial and Global Medical at BMS, a role created to integrate R&D, commercial, and medical decision-making.

Gwendolyn Binder, Ph.D. President, Science & Technology

Dr. Binder joined Cabaletta Bio in February 2019 as one of its first employees, establishing and leading the preclinical, translational, manufacturing, and quality organizations. She was promoted to President of Science and Technology in January 2022. Before Cabaletta, Dr. Binder was the Chief Technology Officer of Adaptimmune Therapeutics Plc, where she established early clinical, translational research, and manufacturing functions in the U.S. arm of the company. She also served as Director of Translational Research Operations at the University of Pennsylvania, where she progressed multiple Investigational New Drug (IND) applications for novel engineered T-cell therapies.

Samik Basu, M.D. Chief Scientific Officer

Dr. Basu joined Cabaletta Bio in December 2019. He previously held the role of Vice President of Preclinical Research and Translational Medicine at Cabaletta before becoming Chief Scientific Officer, overseeing discovery, preclinical, computational biology, and translational medicine research. Prior to Cabaletta, Dr. Basu was Head of Translational Sciences (Medicine) at Adaptimmune Therapeutics, Plc. He also co-led preclinical development efforts for Keytruda (pembrolizumab) at Merck Research Laboratories.

Arun Das, M.D. Chief Business Officer

Dr. Das joined Cabaletta Bio in July 2019 and was promoted to Chief Business Officer from his previous role as Executive Director of New Product Planning and Business Development. Before joining Cabaletta, he was a resident physician in General Pediatrics at the Children's Hospital of Philadelphia. Additionally, Dr. Das worked as an investment banking analyst within the healthcare group at Goldman Sachs.

The key risks to Cabaletta Bio (CABA) are primarily associated with its status as a clinical-stage biotechnology company developing novel cell therapies for autoimmune diseases:

1. Clinical Trial Success, Safety, and Regulatory Approval: As a clinical-stage company, Cabaletta Bio's business success is heavily dependent on the successful completion of its clinical trials, particularly for its lead product candidate, rese-cel (also known as CABA-201). There is inherent uncertainty in the outcomes of clinical trials, and failure can occur at any stage, including unexpected safety or efficacy data. While initial clinical data has shown promise, risks such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have been observed, although some events have been linked to protocol deviations. Ultimately, obtaining regulatory approval from agencies like the FDA is a long, complex, and uncertain process, and delays or failures in this regard could significantly impact the company's prospects.
2. Intense Competition in the CAR-T Therapy Space: Cabaletta Bio operates in a highly competitive biotechnology landscape. There is increasing competition in the CAR-T therapy space for autoimmune diseases, including from larger pharmaceutical companies and other well-funded biotech innovators who are also developing cell therapies. This competition could impact market share, pricing power, and the overall commercial viability of Cabaletta's product candidates if they reach the market.
3. Financial Stability and Need for Additional Funding: As a company primarily focused on research and development with no commercialized products generating revenue, Cabaletta Bio incurs substantial operating expenses, particularly for its R&D programs. The company relies on external funding to advance its pipeline, and while it has bolstered its financial position through fundraising, a "going-concern" warning has been noted in past financial reports, indicating a reliance on future financing. There is a risk of needing substantial additional funding, which could lead to dilution for existing shareholders.

Cabaletta Bio, Inc. is developing engineered T cell therapies for various B cell-mediated autoimmune diseases. The addressable markets for their main products are as follows:

Pemphigus Vulgaris (including Mucosal Pemphigus Vulgaris and Mucocutaneous Pemphigus Vulgaris)

• The global pemphigus vulgaris market was estimated at approximately USD 481.3 million in 2024 and is projected to reach USD 975.2 million by 2033, demonstrating a Compound Annual Growth Rate (CAGR) of 8.2% from 2025 to 2033.
• Another estimate places the global pemphigus vulgaris market at USD 530.43 million in 2025, growing to USD 574.19 million in 2026, and projected to reach around USD 1171.93 million by 2035.
• North America held the largest global revenue share of 38.1% in the pemphigus vulgaris market in 2024. The U.S. Pemphigus Vulgaris Market is estimated at USD 240.7 million in 2024 and is projected to reach USD 330.5 million by 2030.

Hemophilia A with Factor VIII Alloantibodies (including FVIII-CAART for Hemophilia A)

• The Hemophilia Inhibitors market, which specifically addresses alloantibodies to clotting factors like Factor VIII, was valued at approximately USD 16.43 billion globally in 2025 and is forecast to reach USD 29.54 billion by 2035, expanding at a CAGR of 6.04% from 2026 to 2035.
• For the broader Hemophilia A market, the market size in the 7MM (United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan) was USD 12.2 billion in 2024.
• The United States accounted for the largest Hemophilia A treatment market size, approximately 48% of the total market in the 7MM in 2024.
• Globally, the hemophilia market size was estimated at USD 14.11 billion in 2024 and is projected to reach USD 21.07 billion by 2030, with Hemophilia A holding the largest share of 73.97% in 2024.

Myasthenia Gravis

• The global myasthenia gravis treatment market was valued at USD 1.8 billion in 2024 and is expected to grow to USD 3.8 billion by 2034, at a CAGR of 7.6%.
• Another report estimates the global myasthenia gravis market size to be USD 1.3 billion in 2023, with a projection to reach USD 2.1 billion by 2034.
• North America held a significant market share of USD 700.0 million in 2024 for the Myasthenia Gravis market. The U.S. myasthenia gravis treatment industry was valued at USD 733.3 million in 2024.

1. Regulatory Approval and Commercialization of rese-cel for Myositis: Cabaletta Bio is actively enrolling a 17-patient registrational cohort for myositis, aiming for a Biologics License Application (BLA) submission for rese-cel in 2027. Successful regulatory approval and subsequent market launch for this indication represent the most direct pathway to initial revenue generation for the company.
2. Expansion of rese-cel into Additional Autoimmune Indications: Beyond myositis, Cabaletta Bio is strategically pursuing the development of rese-cel for a range of other B cell-mediated autoimmune diseases. The company has achieved FDA alignment on registrational cohort designs for Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN), and rese-cel has been granted Regenerative Medicine Advanced Therapy (RMAT) designation for systemic sclerosis. Ongoing trials in generalized myasthenia gravis and pemphigus vulgaris further broaden the pipeline. Successful clinical development and subsequent regulatory approvals for these additional indications would significantly expand rese-cel's addressable market and contribute to long-term revenue growth.
3. Advancements in Manufacturing and Administration to Enhance Market Adoption: Cabaletta Bio's efforts to implement fully automated manufacturing of rese-cel using the Cellares platform, with clinical manufacturing data expected in the first half of 2026, aim to establish a scalable commercial business with attractive margins. Furthermore, the exploration of a "no preconditioning" regimen for rese-cel in certain indications like pemphigus vulgaris and systemic lupus erythematosus could simplify the treatment process, potentially broadening patient eligibility and accelerating physician adoption, thereby increasing market penetration and revenue.
4. Geographic Market Expansion: The company's expansion of its clinical footprint, including 40 active clinical sites in the U.S. and an anticipated extension into Europe in 2025, sets the groundwork for future international regulatory approvals and commercialization. This geographic expansion is crucial for maximizing the global revenue potential of rese-cel upon its market entry.

Share Issuance

• Cabaletta Bio's outstanding shares significantly increased over the last few years, from approximately 28.34 million in 2021 to about 102.26 million at the end of 2025, reflecting substantial share issuances.
• In January 2026, the Chief Commercial Officer, Steve Gavel, purchased 22,170 shares for approximately $50,317.90, and the General Counsel, Michael Gerard, acquired 6,600 shares for approximately $14,979.
• The President, Science & Tech, Gwendolyn Binder, was granted 225,000 stock options in March 2026, which are set to vest over time.

Inbound Investments

• Millennium Management LLC acquired an additional 2,393,851 shares of Cabaletta Bio on February 11, 2026, at $2.57 per share, totaling approximately $6.15 million and increasing their total holdings to 5.30% of the traded stock.

Capital Expenditures

• Cabaletta Bio had capital expenditures of approximately $1.4 million over the last 12 months.
• The company secured its office and laboratory space through an amended lease agreement from October 1, 2024, through at least August 31, 2026, with monthly rent around $240,000, totaling an estimated $5.5 million for the initial term, primarily focused on supporting ongoing research and development activities.
• Cabaletta Bio's strategic priorities for 2026 include advancing innovations to efficiently increase scale through automated manufacturing, aiming for minimal capital investment by utilizing platforms like Cellares' fully automated Cell Shuttle and Cell Q for clinical manufacturing of its investigational CAR T therapy, rese-cel.